RazelleKurzrockMD

Chief, Division of Hematology & Oncology Sr. Deputy Center Director, Clinical Science, Director, Center for Personalized Cancer Therapy and Clinical Trials Office, UC San Diego Moores Cancer Center

Join to view full profile

Dr. Kurzrock is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Kurzrock's full profile

Already have an account?

Office
9200 W Wisconsin Ave
Milwaukee, WI 53226
Phone+1 414-805-0505

Fax+1 414-805-6808

Education & Training

University of Texas Health Science Center at HoustonResidency, Internal Medicine, 1982 - 1983
Tulane UniversityResidency, Internal Medicine, 1979 - 1981
University of Toronto Faculty of MedicineClass of 1978

Certifications & Licensure

FL State Medical License 2021 - Present
NY State Medical License 1986 - Present
TX State Medical License 1984 - 2026
CA State Medical License 2014 - 2025
WI State Medical License 2022 - 2025
LA State Medical License 1979 - 1984
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Elected Member The American Society for Clinical Investigation, 1997

Clinical Trials

Amifostine in Treating Patients With Myelodysplastic Syndrome Start of enrollment: 1997 Jun 05
Completed
Phase 2
Tipifarnib in Treating Patients With Myelodysplastic Syndromes Start of enrollment: 2002 Jun 01
Completed
Phase 1
PEG-Intron For Chronic Myelogenous Leukemia Patients Unresponsive To Or Intolerant Of Roferon Or Intron Start of enrollment: 2001 Feb 01
Terminated
Phase 2
A Study Of Deoxycoformycin(DCF)/Pentostatin In Lymphoid Malignancies Start of enrollment: 1994 Sep 06
Completed
Phase 2
Phase II Study Of Roferon and Accutane For Patients With T-Cell Malignancies Start of enrollment: 1990 May 08
Completed
Phase 2
Imatinib Mesylate in Treating Patients With Stage IV Colorectal Cancer Start of enrollment: 2002 May 01
Completed
Phase 2
Tipifarnib and Sorafenib Tosylate in Treating Patients With Biopsiable Advanced Cancer Start of enrollment: 2005 Oct 01
Completed
Phase 1
Study of Atiprimod Treatment for Patients With Advanced Cancer Start of enrollment: 2005 Mar 01
Terminated
Phase 1
Azacytidine and Valproic Acid in Patients With Advanced Cancers Start of enrollment: 2005 May 01
Completed
Phase 1
Phase I Trial of ZIO-101 in Patients With Solid Tumors Start of enrollment: 2005 May 01
Completed
Phase 1
A Phase I, Study to Evaluate the Safety and Tolerability of Intravenous EZN-2208 in Patients With Advanced Solid Tumors or Lymphoma (EZN-2208-01) Start of enrollment: 2007 May 01
Completed
Phase 1
Bevacizumab and Temsirolimus in Patients With Advanced Malignancy Start of enrollment: 2008 Jan 25
Completed
Phase 1
Study of Temsirolimus, Topotecan, and Bortezomib Start of enrollment: 2008 Sep 01
Completed
Phase 1
Phosphatidylinositol 3 Kinase and Mammalian Target of Rapamycin (PI3K-mTOR) in Advanced Cancer Patients Start of enrollment: 2009 Apr 01
Terminated
Phase 1, Phase 2
FLT-PET as an Imaging Biomarker With Temsirolimus, Topotecan, and Bortezomib Start of enrollment: 2010 Jun 01
Completed
Phase 1
Temsirolimus In Phase 0 Start of enrollment: 2010 Aug 01
Completed
Early Phase 1
Phase 1 Trial With SIR-Spheres and Cetuximab +/- Erlotinib Start of enrollment: 2012 Dec 01
Withdrawn
Phase 1
Survival Prolongation by Rationale Innovative Genomics Start of enrollment: 2017 Nov 29
Terminated
Phase 1, Phase 2
The Registry of Oncology Outcomes Associated With Testing and Treatment Start of enrollment: 2021 May 05
Recruiting
Join now to see all

Publications & Presentations

PubMed

SWOG/NCI Phase II Dual Anti-CTLA-4/PD-1 Blockade in Rare Tumors: Nonepithelial Ovarian Cancer.
Young Kwang Chae, Megan Othus, Sandip Pravin Patel, Kelly J Wilkinson, Emily M Whitman-Purves
Clinical Cancer Research. 2024-12-16
Measurable Residual Disease in Mantle Cell Lymphoma: The Unbearable Lightness of Being Undetectable.
Julio Cartagena, Anagha Deshpande, Allison Rosenthal, Mazie Tsang, Talal Hilal
Current Oncology Reports. 2024-12-01
2 citations
Healthcare disparities, screening, and molecular testing in the changing landscape of non-small cell lung cancer in the United States: a review.
Razelle Kurzrock, Aadel A Chaudhuri, David Feller-Kopman, Narjust Florez, Jed Gorden
Cancer Metastasis Reviews. 2024-12-01

Journal Articles

International, Evidence-Based Consensus Treatment Guidelines for Idiopathic Multicentric Castleman Disease
Aaron Goodman, Corey Casper, Sudipto Mukherjee, Peter Voorhees, Angela Dispenzieri, David C Fajgenbaum, Amy Chadburn, Razelle Kurzrock, Raj Jayanthan, Sunita Nasta, Th..., Blood
Preoperative Circulating Tumor DNA in Patients with Peritoneal Carcinomatosis Is an Independent Predictor of Progression-Free Survival
Andrew M Lowy, Kaitlyn J Kelly, Joel M Baumgartner, Lisa Tran, Razelle Kurzrock, Annals of Surgical Oncology

Abstracts/Posters